Global Monoclonal Mouse Antibody

Monoclonal Mouse Antibody Comprehensive Study by Type (IgM, IgG, IgA, Others), Application (Therapeutic, Research, Diagnostic), Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others), Production Type (In Vivo, In Vitro) Players and Region - Global Market Outlook to 2028

Monoclonal Mouse Antibody Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Monoclonal Mouse Antibody Market Scope
Mouse monoclonal antibody is produced by injecting an antigen into a mouse to initiate a humoral immune response. It has many features including targeting a single epitope, stable passage, high specificity, large-scale manufacturing, and extensive applications in basic research, tumor therapy, medical diagnosis, and radio immunoimaging.

AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledPfizer (United States), Bayer AG (Germany), Eli Lilly and Company (United States), Roche Holding AG (Switzerland), Johnson & Johnson (United States), Merck & Co. (United States), Novartis International AG (Switzerland), AbbVie Inc. (United States), GlaxoSmithKline (United Kingdom), Amgen Inc. (United States) and Bristol-Myers Squibb (United States)
CAGR%


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Monoclonal Mouse Antibody market throughout the predicted period.

Pfizer (United States), Bayer AG (Germany), Eli Lilly and Company (United States), Roche Holding AG (Switzerland), Johnson & Johnson (United States), Merck & Co. (United States), Novartis International AG (Switzerland), AbbVie Inc. (United States), GlaxoSmithKline (United Kingdom), Amgen Inc. (United States) and Bristol-Myers Squibb (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Biogen Inc. (Switzerland), AstraZeneca plc (United Kingdom), Sanofi S.A. (France), Alexion Pharmaceuticals Inc. (United States) and Seagen Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Monoclonal Mouse Antibody market by Type , by Application (Therapeutic, Research and Diagnostic) and Region with country level break-up.

On the basis of geography, the market of Monoclonal Mouse Antibody has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
On 13 December 2021, Pfizer Inc. and Arena Pharmaceuticals, Inc. announced a definitive agreement under which Pfizer will acquire Arena, a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all of Arena's outstanding shares in an all-cash transaction for USD 100 per share, for a total equity value of approximately USD 6.7 billion. Both companies boards of directors unanimously approved the transaction.
In June 2021, Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083. It is a completely human, anti-OX40 monoclonal antibody in Phase 3-ready development by Kyowa Kirin with the potential to treat various autoimmune illnesses in addition to treating atopic dermatitis.
MNGPKL is a monoclonal antibody that recognizes mouse interferon regulatory factor 7 (IRF7), a 54 kDa transcription factor required for the induction of the antiviral innate immune response and the production of IFN alpha. IRF7 is expressed constitutively in the cytoplasm of B cells, plasmacytoid dendritic cells (pDC), and monocytes until activated by a viral infection, double-stranded RNA, or Toll-like receptor (TLR) signaling. CpG ODNs and single-stranded RNA, which are recognized by CD289 (TLR9) and TLR7, respectively, activate and upregulate IRF7. This activation stimulates the production of type I IFN, which disrupts the pathogen and viral infection. These events result in IRF7 phosphorylation and translocation to the nucleus, where it forms a homodimer and regulates transcription.

Influencing Trend:
Technological Advancements in The Medical Science

Market Growth Drivers:
Increased Prevalence of Chronic Diseases and Increased Research and Development Activities

Challenges:
Stringent Government Rules and Regulations

Restraints:
High Cost for Research and Development Investment

Opportunities:
Increased Government Funding for Healthcare Sector and Growth in the Healthcare Sectors Worldwide

Key Target Audience
Monoclonal Mouse Antibody Producers, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • IgM
  • IgG
  • IgA
  • Others
By Application
  • Therapeutic
  • Research
  • Diagnostic
By Indication
  • Cancer
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Microbial Diseases
  • Others

By Production Type
  • In Vivo
  • In Vitro

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Chronic Diseases
      • 3.2.2. Increased Research and Development Activities
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in The Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Monoclonal Mouse Antibody, by Type, Application, Indication, Production Type and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Monoclonal Mouse Antibody (Value)
      • 5.2.1. Global Monoclonal Mouse Antibody by: Type (Value)
        • 5.2.1.1. IgM
        • 5.2.1.2. IgG
        • 5.2.1.3. IgA
        • 5.2.1.4. Others
      • 5.2.2. Global Monoclonal Mouse Antibody by: Application (Value)
        • 5.2.2.1. Therapeutic
        • 5.2.2.2. Research
        • 5.2.2.3. Diagnostic
      • 5.2.3. Global Monoclonal Mouse Antibody by: Indication (Value)
        • 5.2.3.1. Cancer
        • 5.2.3.2. Autoimmune Diseases
        • 5.2.3.3. Inflammatory Diseases
        • 5.2.3.4. Infectious Diseases
        • 5.2.3.5. Microbial Diseases
        • 5.2.3.6. Others
      • 5.2.4. Global Monoclonal Mouse Antibody by: Production Type (Value)
        • 5.2.4.1. In Vivo
        • 5.2.4.2. In Vitro
      • 5.2.5. Global Monoclonal Mouse Antibody Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Monoclonal Mouse Antibody: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis International AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bristol-Myers Squibb (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Monoclonal Mouse Antibody Sale, by Type, Application, Indication, Production Type and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Monoclonal Mouse Antibody (Value)
      • 7.2.1. Global Monoclonal Mouse Antibody by: Type (Value)
        • 7.2.1.1. IgM
        • 7.2.1.2. IgG
        • 7.2.1.3. IgA
        • 7.2.1.4. Others
      • 7.2.2. Global Monoclonal Mouse Antibody by: Application (Value)
        • 7.2.2.1. Therapeutic
        • 7.2.2.2. Research
        • 7.2.2.3. Diagnostic
      • 7.2.3. Global Monoclonal Mouse Antibody by: Indication (Value)
        • 7.2.3.1. Cancer
        • 7.2.3.2. Autoimmune Diseases
        • 7.2.3.3. Inflammatory Diseases
        • 7.2.3.4. Infectious Diseases
        • 7.2.3.5. Microbial Diseases
        • 7.2.3.6. Others
      • 7.2.4. Global Monoclonal Mouse Antibody by: Production Type (Value)
        • 7.2.4.1. In Vivo
        • 7.2.4.2. In Vitro
      • 7.2.5. Global Monoclonal Mouse Antibody Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Monoclonal Mouse Antibody: by Type(USD Million)
  • Table 2. Monoclonal Mouse Antibody IgM , by Region USD Million (2017-2022)
  • Table 3. Monoclonal Mouse Antibody IgG , by Region USD Million (2017-2022)
  • Table 4. Monoclonal Mouse Antibody IgA , by Region USD Million (2017-2022)
  • Table 5. Monoclonal Mouse Antibody Others , by Region USD Million (2017-2022)
  • Table 6. Monoclonal Mouse Antibody: by Application(USD Million)
  • Table 7. Monoclonal Mouse Antibody Therapeutic , by Region USD Million (2017-2022)
  • Table 8. Monoclonal Mouse Antibody Research , by Region USD Million (2017-2022)
  • Table 9. Monoclonal Mouse Antibody Diagnostic , by Region USD Million (2017-2022)
  • Table 10. Monoclonal Mouse Antibody: by Indication(USD Million)
  • Table 11. Monoclonal Mouse Antibody Cancer , by Region USD Million (2017-2022)
  • Table 12. Monoclonal Mouse Antibody Autoimmune Diseases , by Region USD Million (2017-2022)
  • Table 13. Monoclonal Mouse Antibody Inflammatory Diseases , by Region USD Million (2017-2022)
  • Table 14. Monoclonal Mouse Antibody Infectious Diseases , by Region USD Million (2017-2022)
  • Table 15. Monoclonal Mouse Antibody Microbial Diseases , by Region USD Million (2017-2022)
  • Table 16. Monoclonal Mouse Antibody Others , by Region USD Million (2017-2022)
  • Table 17. Monoclonal Mouse Antibody: by Production Type(USD Million)
  • Table 18. Monoclonal Mouse Antibody In Vivo , by Region USD Million (2017-2022)
  • Table 19. Monoclonal Mouse Antibody In Vitro , by Region USD Million (2017-2022)
  • Table 20. South America Monoclonal Mouse Antibody, by Country USD Million (2017-2022)
  • Table 21. South America Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 22. South America Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 23. South America Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 24. South America Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 25. Brazil Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 26. Brazil Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 27. Brazil Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 28. Brazil Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 29. Argentina Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 30. Argentina Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 31. Argentina Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 32. Argentina Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 33. Rest of South America Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 35. Rest of South America Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 36. Rest of South America Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 37. Asia Pacific Monoclonal Mouse Antibody, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 40. Asia Pacific Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 41. Asia Pacific Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 42. China Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 43. China Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 44. China Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 45. China Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 46. Japan Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 47. Japan Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 48. Japan Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 49. Japan Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 50. India Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 51. India Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 52. India Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 53. India Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 54. South Korea Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 55. South Korea Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 56. South Korea Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 57. South Korea Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 58. Taiwan Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 59. Taiwan Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 60. Taiwan Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 61. Taiwan Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 62. Australia Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 63. Australia Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 64. Australia Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 65. Australia Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 70. Europe Monoclonal Mouse Antibody, by Country USD Million (2017-2022)
  • Table 71. Europe Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 72. Europe Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 73. Europe Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 74. Europe Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 75. Germany Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 76. Germany Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 77. Germany Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 78. Germany Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 79. France Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 80. France Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 81. France Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 82. France Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 83. Italy Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 84. Italy Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 85. Italy Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 86. Italy Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 87. United Kingdom Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 89. United Kingdom Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 90. United Kingdom Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 91. Netherlands Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 92. Netherlands Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 93. Netherlands Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 94. Netherlands Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 95. Rest of Europe Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 97. Rest of Europe Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 98. Rest of Europe Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 99. MEA Monoclonal Mouse Antibody, by Country USD Million (2017-2022)
  • Table 100. MEA Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 101. MEA Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 102. MEA Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 103. MEA Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 104. Middle East Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 105. Middle East Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 106. Middle East Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 107. Middle East Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 108. Africa Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 109. Africa Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 110. Africa Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 111. Africa Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 112. North America Monoclonal Mouse Antibody, by Country USD Million (2017-2022)
  • Table 113. North America Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 114. North America Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 115. North America Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 116. North America Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 117. United States Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 118. United States Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 119. United States Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 120. United States Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 121. Canada Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 122. Canada Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 123. Canada Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 124. Canada Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 125. Mexico Monoclonal Mouse Antibody, by Type USD Million (2017-2022)
  • Table 126. Mexico Monoclonal Mouse Antibody, by Application USD Million (2017-2022)
  • Table 127. Mexico Monoclonal Mouse Antibody, by Indication USD Million (2017-2022)
  • Table 128. Mexico Monoclonal Mouse Antibody, by Production Type USD Million (2017-2022)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Monoclonal Mouse Antibody: by Type(USD Million)
  • Table 141. Monoclonal Mouse Antibody IgM , by Region USD Million (2023-2028)
  • Table 142. Monoclonal Mouse Antibody IgG , by Region USD Million (2023-2028)
  • Table 143. Monoclonal Mouse Antibody IgA , by Region USD Million (2023-2028)
  • Table 144. Monoclonal Mouse Antibody Others , by Region USD Million (2023-2028)
  • Table 145. Monoclonal Mouse Antibody: by Application(USD Million)
  • Table 146. Monoclonal Mouse Antibody Therapeutic , by Region USD Million (2023-2028)
  • Table 147. Monoclonal Mouse Antibody Research , by Region USD Million (2023-2028)
  • Table 148. Monoclonal Mouse Antibody Diagnostic , by Region USD Million (2023-2028)
  • Table 149. Monoclonal Mouse Antibody: by Indication(USD Million)
  • Table 150. Monoclonal Mouse Antibody Cancer , by Region USD Million (2023-2028)
  • Table 151. Monoclonal Mouse Antibody Autoimmune Diseases , by Region USD Million (2023-2028)
  • Table 152. Monoclonal Mouse Antibody Inflammatory Diseases , by Region USD Million (2023-2028)
  • Table 153. Monoclonal Mouse Antibody Infectious Diseases , by Region USD Million (2023-2028)
  • Table 154. Monoclonal Mouse Antibody Microbial Diseases , by Region USD Million (2023-2028)
  • Table 155. Monoclonal Mouse Antibody Others , by Region USD Million (2023-2028)
  • Table 156. Monoclonal Mouse Antibody: by Production Type(USD Million)
  • Table 157. Monoclonal Mouse Antibody In Vivo , by Region USD Million (2023-2028)
  • Table 158. Monoclonal Mouse Antibody In Vitro , by Region USD Million (2023-2028)
  • Table 159. South America Monoclonal Mouse Antibody, by Country USD Million (2023-2028)
  • Table 160. South America Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 161. South America Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 162. South America Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 163. South America Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 164. Brazil Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 165. Brazil Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 166. Brazil Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 167. Brazil Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 168. Argentina Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 169. Argentina Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 170. Argentina Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 171. Argentina Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 172. Rest of South America Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 173. Rest of South America Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 174. Rest of South America Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 175. Rest of South America Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 176. Asia Pacific Monoclonal Mouse Antibody, by Country USD Million (2023-2028)
  • Table 177. Asia Pacific Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 178. Asia Pacific Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 179. Asia Pacific Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 180. Asia Pacific Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 181. China Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 182. China Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 183. China Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 184. China Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 185. Japan Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 186. Japan Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 187. Japan Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 188. Japan Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 189. India Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 190. India Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 191. India Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 192. India Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 193. South Korea Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 194. South Korea Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 195. South Korea Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 196. South Korea Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 197. Taiwan Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 198. Taiwan Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 199. Taiwan Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 200. Taiwan Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 201. Australia Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 202. Australia Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 203. Australia Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 204. Australia Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 209. Europe Monoclonal Mouse Antibody, by Country USD Million (2023-2028)
  • Table 210. Europe Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 211. Europe Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 212. Europe Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 213. Europe Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 214. Germany Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 215. Germany Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 216. Germany Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 217. Germany Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 218. France Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 219. France Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 220. France Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 221. France Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 222. Italy Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 223. Italy Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 224. Italy Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 225. Italy Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 226. United Kingdom Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 227. United Kingdom Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 228. United Kingdom Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 229. United Kingdom Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 230. Netherlands Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 231. Netherlands Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 232. Netherlands Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 233. Netherlands Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 234. Rest of Europe Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 235. Rest of Europe Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 236. Rest of Europe Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 237. Rest of Europe Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 238. MEA Monoclonal Mouse Antibody, by Country USD Million (2023-2028)
  • Table 239. MEA Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 240. MEA Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 241. MEA Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 242. MEA Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 243. Middle East Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 244. Middle East Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 245. Middle East Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 246. Middle East Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 247. Africa Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 248. Africa Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 249. Africa Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 250. Africa Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 251. North America Monoclonal Mouse Antibody, by Country USD Million (2023-2028)
  • Table 252. North America Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 253. North America Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 254. North America Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 255. North America Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 256. United States Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 257. United States Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 258. United States Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 259. United States Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 260. Canada Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 261. Canada Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 262. Canada Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 263. Canada Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 264. Mexico Monoclonal Mouse Antibody, by Type USD Million (2023-2028)
  • Table 265. Mexico Monoclonal Mouse Antibody, by Application USD Million (2023-2028)
  • Table 266. Mexico Monoclonal Mouse Antibody, by Indication USD Million (2023-2028)
  • Table 267. Mexico Monoclonal Mouse Antibody, by Production Type USD Million (2023-2028)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Monoclonal Mouse Antibody: by Type USD Million (2017-2022)
  • Figure 5. Global Monoclonal Mouse Antibody: by Application USD Million (2017-2022)
  • Figure 6. Global Monoclonal Mouse Antibody: by Indication USD Million (2017-2022)
  • Figure 7. Global Monoclonal Mouse Antibody: by Production Type USD Million (2017-2022)
  • Figure 8. South America Monoclonal Mouse Antibody Share (%), by Country
  • Figure 9. Asia Pacific Monoclonal Mouse Antibody Share (%), by Country
  • Figure 10. Europe Monoclonal Mouse Antibody Share (%), by Country
  • Figure 11. MEA Monoclonal Mouse Antibody Share (%), by Country
  • Figure 12. North America Monoclonal Mouse Antibody Share (%), by Country
  • Figure 13. Global Monoclonal Mouse Antibody share by Players 2022 (%)
  • Figure 14. Global Monoclonal Mouse Antibody share by Players (Top 3) 2022(%)
  • Figure 15. Global Monoclonal Mouse Antibody share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2022
  • Figure 19. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 21. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 23. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 25. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 26. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 27. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 29. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 31. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 33. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 35. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 38. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 39. Global Monoclonal Mouse Antibody: by Type USD Million (2023-2028)
  • Figure 40. Global Monoclonal Mouse Antibody: by Application USD Million (2023-2028)
  • Figure 41. Global Monoclonal Mouse Antibody: by Indication USD Million (2023-2028)
  • Figure 42. Global Monoclonal Mouse Antibody: by Production Type USD Million (2023-2028)
  • Figure 43. South America Monoclonal Mouse Antibody Share (%), by Country
  • Figure 44. Asia Pacific Monoclonal Mouse Antibody Share (%), by Country
  • Figure 45. Europe Monoclonal Mouse Antibody Share (%), by Country
  • Figure 46. MEA Monoclonal Mouse Antibody Share (%), by Country
  • Figure 47. North America Monoclonal Mouse Antibody Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Bayer AG (Germany)
  • Eli Lilly and Company (United States)
  • Roche Holding AG (Switzerland)
  • Johnson & Johnson (United States)
  • Merck & Co. (United States)
  • Novartis International AG (Switzerland)
  • AbbVie Inc. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Amgen Inc. (United States)
  • Bristol-Myers Squibb (United States)
Additional players considered in the study are as follows:
Biogen Inc. (Switzerland) , AstraZeneca plc (United Kingdom) , Sanofi S.A. (France) , Alexion Pharmaceuticals Inc. (United States) , Seagen Inc. (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 202 Pages 57 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Monoclonal Mouse Antibody Quantitative research analysis
Global Monoclonal Mouse Antibody Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Monoclonal Mouse Antibody Market are by type [IgM, IgG, IgA and Others], by end use application [Therapeutic, Research and Diagnostic].
The Monoclonal Mouse Antibody Market is gaining popularity and expected to see strong valuation by 2028.
  • Increased Prevalence of Chronic Diseases
  • Increased Research and Development Activities

Know More About Global Monoclonal Mouse Antibody Report?

Have a Query? Click Here

Other Related Reports

Flow Cytometers Comprehensive Study by Application (Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Hematology), Technology (Cell-based, Bead-based), End use (H...
$ 3650
Porcine Serum Comprehensive Study by Application (Mycoplasmas and Viruses Culture, Lymphocytes Culture, Vaccine Production, Others), Packaging (100 mL, 500 mL, 1000 mL, Others) Players and Region - G...
$ 3500
Antimicrobial Packaging Comprehensive Study by Type (Pouches, Carton Packages, Bags, Trays, Cups & Lids, Others), Application (Food & Beverages, Personal Care, Healthcare, Others), Antimicrobial Agen...
$ 3650
Podophyllotoxin Comprehensive Study by Type (Purity 95%, Purity 98%, Other), Application (Chemical Reagents, Pharmaceutical Intermediates, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Mitogen Activated Protein Kinase 8 Comprehensive Study by Type (CC-90001, SR-3306, ER-358063, WBZ-4, Others), Application (Breast Cancer, Alzheimer's Disease, Acute Renal Failure, Liver Failure, Othe...
$ 3500
Viral Clearance Service Comprehensive Study by Application (Recombinant Proteins, Blood and Blood Products, Vaccines, Other), End-User (Pharmaceutical & Biotechnology Companies, Contract Research Org...
$ 3650